MYGN Related Upgrades
-
Mizuho Securities Upgrades Myriad Genetics (MYGN) to Buy
-
BofA/Merrill Lynch Upgrades Myriad Genetics (MYGN) to Buy
-
Piper Jaffray Upgrades Myriad Genetics (MYGN) to Overweight
-
Goldman Sachs Upgrades Myriad Genetics (MYGN) to Buy
-
Leerink Swann Upgrades Myriad Genetics (MYGN) to Outperform; Growth Prospects Good, Risks Overdone
-
Cowen Upgrades Myriad Genetics (MYGN) to Outperform
-
Ticonderoga Upgrades Myriad Genetics (MYGN) to Buy
-
Goldman Sachs Upgrades Myriad Genetics (MYGN) to Neutral
-
Auriga Upgrades Myriad Genetics (MYGN) to Buy; Patience Will Be Rewarded
-
RBC Capital Upgrades Myriad Genetics (MYGN) to Outperform
-
Auriga Upgrades Myriad Genetics (MYGN) Two Notches as Street Expectations Come Down to More Realistic Levels
-
Auriga Upgrades Myriad Genetics (MYGN) from Sell to Buy; The Bar Has Been Reset
-
Piper Jaffray Positive On Med Tech Stocks In '10
-
Morgan Joseph Upgrades Myriad Genetics (MYGN) to Hold; Expect Positive Sales
-
Canaccord Adams Upgrades Myriad Genetics (MYGN) to Buy
-
Benchmark Capital Upgrades Myriad Genetics (MYGN) to Buy
-
Citi Upgrades Myriad Genetics (MYGN) to Buy
-
RBC Capital Upgrades Myriad Genetics (MYGN) to Outperform
-
RBC Upgrades Myriad Genetics (MYGN) to Sector Perform
-
JMP Securities upgrades MYGN to Strong Buy
-
Merrill Lynch Upgrades MYGN
Back to MYGN Stock Lookup
